STORY SUMMARY

FDA Approves First Gene Therapy for Pediatric Patients with Sanfilippo Syndrome Type A

The U.S. Food and Drug Administration today approved Fayuvi (rebisufligene etisparvovec-hopf), the first treatment for pediatric patients with mucopolysaccharidosis type IIIA (MPS IIIA), also known as Sanfilippo syndrome type A.

This is a brief summary of reporting from FDA Press Releases. Read the original for the full article and context.

Read original reporting ↗

More from FDA Press Releases · Latest headlines